Matthew Read on Saba block of Herald tender

Biotech trusts top performance charts in February

Matthew Read commented on Saba’s latest move in Michael Nelson’s article:

“Matthew Read, senior analyst at QuotedData, said that by not tendering its shares, the implication is that Saba is looking for something else other than an exit at asset value.”

Read the article here